The genomic and transcriptomic landscapes of breast cancer have been extensively studied, but the proteomes of breast tumors are far less characterized. Here, we use high-resolution, high-accuracy mass spectrometry to perform a deep analysis of luminal-type breast cancer progression using clinical breast samples from primary tumors, matched lymph node metastases, and healthy breast epithelia. We used a super-SILAC mix to quantify over 10,000 proteins with high accuracy, enabling us to identify key proteins and pathways associated with tumorigenesis and metastatic spread. We found high expression levels of proteins associated with protein synthesis and degradation in cancer tissues, accompanied by metabolic alterations that may facilitate energy production in cancer cells within their natural environment. In addition, we found proteomic differences between breast cancer stages and minor differences between primary tumors and their matched lymph node metastases. These results highlight the potential of proteomic technology in the elucidation of clinically relevant cancer signatures.
INTRODUCTION
Over the past decade, there has been a tremendous progress in the characterization of fundamental molecular determinants of breast cancer. The development of high throughput technologies has made it possible to approach the disease in a global manner and assess the contribution of the DNA, the RNA, and the proteins to the tumorigenic phenotype. While the genomic and transcriptomic levels have been extensively studied, the proteomic level has been mainly studied using cell lines or with low analytical depth due to technological challenges Lam et al., 2014; Lawrence et al., 2015; Sørlie, 2007; Zeidan et al., 2015) . Seminal gene expression studies defined molecular signatures that allowed the classification of breast tumors into four accepted ''intrinsic'' subtypes: luminal A and B, Her2-overexpressing, and basal-like tumors (Perou et al., 2000; Sørlie et al., 2001) . Further genomic and transcriptomic efforts expanded and refined the original signatures to slightly alter the classification (Prat and Perou, 2011) . These efforts culminated in the publication of two exceptional studies in 2012, which make up the largest breast cancer genomic profiling done to date, combining data from multiple platforms and utilizing next-generation sequencing techniques to study up to 2,000 breast tumors (Curtis et al., 2012; Cancer Genome Atlas Network, 2012) . These genomic and transcriptomic data serve as an invaluable resource of breast cancer-associated mutations, chromosomal aberrations and further expanded the classification to additional subtypes. However, the actual manifestation of such genomic changes in the cancer phenotype is far from obvious.
Clinical assessment of the intrinsic subtypes showed their relevance to the determination of breast cancer prognosis (Sørlie et al., 2003) . Luminal tumors make up the vast majority of breast tumors and are characterized by expression of the estrogen receptor (ER). As such, they can be treated by endocrine therapy such as Tamoxifen (Ellis and Perou, 2013) . Luminal A tumors show overall favorable prognosis, while luminal B, which also express higher levels of the proliferation marker ki67 or Her2, have poorer prognosis. Despite the overall good prognosis of the luminal tumors, risk of recurrence rises substantially if the cancer had already metastasized to nearby lymph nodes by the time of diagnosis (lymph node-positive [LNP] ) (Chia et al., 2012) . While lymph node-negative (LNN) patients may benefit from endocrine therapy alone, the standard of care for LNP patients remains adjuvant chemotherapy (Henry and Hayes, 2007) , hence the lymph node status is emphasized as a crucial component in treatment decision-making.
Proteomics makes a natural complement to the genomic and transcriptomic studies, as proteins convey the actual functional properties of cells. Mass spectrometry (MS)-based proteomic analyses have undergone a revolution in the past decade, owing to improvements in instrumentation, sample preparation and quantification methods (reviewed in Mann et al., 2013) . The advanced MS instruments combine high resolution, high mass accuracy, and high speed, and are capable of comprehensively cataloguing proteomes of yeast, mouse, and most recently, human (Geiger et al., 2013; Kim et al., 2014; Nagaraj et al., 2012; Wilhelm et al., 2014) . The implementation of proteomics to cancer studies is increasing; however, many of these studies are still limited in scope and quantification accuracy.
Stable isotope labeling with amino acids in cell culture (SILAC) is an accurate relative quantification technique (Ong et al., 2002) . In this metabolic labeling approach, cell lines incorporate heavy or light isotope versions of lysine and arginine into their proteome. When mixed, each protein is present in the solution in two forms (heavy and light), allowing very accurate relative quantification of the proteins in the MS analysis. A SILAC-labeled cell line can be used as a common, ''spike-in,'' internal standard for comparing a theoretically unlimited number of samples, including samples that cannot be metabolically labeled, such as clinical tumor samples (Geiger et al., 2011; Pozniak and Geiger, 2014; Shenoy and Geiger, 2015) . For tumor proteome quantification, we spiked-in the previously developed super-SILAC mix, a mixture of four distinct breast cancer cell lines and primary mammary epithelial cells, which was found to dramatically increase the quantification accuracy of breast cancer proteomes (Geiger et al., 2010) . This technique has been increasingly used for different types of tissues (Aasebø et al., 2014; Deeb et al., 2012; Lund et al., 2012; Zhang et al., 2014) .
Here, we present a wide-scope, genome-scale proteomic analysis of breast cancer progression and compare non-transformed cells, lymph node-negative and -positive lesions, as well as their matched lymph node metastases. This cohort is significantly larger than typical proteomic studies, and analyzing actual clinical samples, rather than cell lines, gives a more accurate picture of tumor behavior. By quantifying in total more than 10,000 proteins, we point to key molecular networks associated with cancer progression.
RESULTS
To gain insights into the proteomic changes that occur during breast cancer progression, we assembled a cohort of formalinfixed, paraffin-embedded (FFPE) breast clinical samples. Since for luminal tumors, patient prognosis largely depends on the lymph node status (Paik et al., 2006) , identification of the processes that are altered upon cancer progression can lead to better understanding of the regulatory mechanisms of cancer. The cohort included 88 samples from different stages of breast cancer, with non-metastatic lesions (lymph node-negative [LNN] , n = 21), lesions with lymph node involved by metastatic carcinoma (lymph node-positive [LNP] , n = 20), their matched lymph node metastases (n = 25), and adjacent healthy ducts as controls (n = 22). All surgical specimens originated from untreated ER-positive, Her2-negative infiltrating ductal carcinomas (IDC, luminal), grades 2 or 3, based on immunohistochemical staining (IHC) and pathologist review ( Figure 1A ; Table S1 ).
To accurately quantify proteins in these samples, we used the previously published breast cancer super-SILAC mix (Geiger et al., 2010) to serve as a common internal standard against which proteins from all samples are quantified in the MS analysis. MaxQuant analysis identified overall 150,471 peptides and 10,124 proteins and quantified overall 10,043 of them (Figures 1B and S1A; false discovery rate [FDR] of 1% on both peptide and protein levels). We found no overall differences in the total number of quantified proteins, between the groups of samples, with 9,093 proteins quantified in the healthy tissue, 9,746 in LNN and LNP tumor tissue, and 9,450 proteins in the metastatic tissue with an average of 5,439 proteins identified and 4,300 quantified in each tissue. From these, 1,499 were identified in all 88 samples, and only 177 were found in <10 of the samples ( Figure S1B ). The combined dynamic range of protein expression levels encompassed eight orders of magnitude but the vast majority of proteins (97%) were expressed within four orders of magnitude ( Figure 1C ). Among these proteins, we identified known luminal breast cancer-associated proteins such as GATA3, FOXA1, and the estrogen receptor ESR. Among the most abundant proteins, we identified histones, actin, and tubulin, as well as ribosomal proteins (see Table S2 for the complete list).
To examine our coverage of breast-related proteins, we compared our dataset to the recently published draft of the human proteome (Wilhelm et al., 2014) . The authors defined a ''core'' proteome comprising of 11,578 proteins, of which we have identified 8,596 (74%). Examination of the group of 1,021 breast tissue-specific proteins (as defined by Wilhelm et al., 2014) , showed significantly higher median expression intensity of 921 proteins identified in this study, compared to the overall protein intensity distribution, in all three clinical groups (Figure 1D ; annotation enrichment, FDR = 0.02) . These results show that we are able to capture higher levels of the breast-specific proteome. To examine the ability of the super-SILAC mix to accurately quantify the proteins in each of the clinical groups, we determined the ratios between the samples and the super-SILAC mix proteins. For all groups of tumors, we found that over 90% of the proteins are within a 5-fold difference from the super-SILAC standard, thus achieving accurate measurement of the ratios ( Figure S1C ). These results endorse our data as providing the technical accuracy and breast cancer relevance of the identified proteins.
The large number of analyzed samples provides a global view of proteins and processes that act together and may be involved in tumor formation. To exploit that, we constructed functional networks based on the correlations between pairs of proteins identified in this study. Pearson correlations with a cutoff of 0.3 were used as a basis for K-means generic clustering (Figure 2 ). The data were divided into ten clusters followed by Fisher exact test to examine enriched processes within each cluster (FDR = 0.02; Table S3 ). This analysis revealed links between distinct cellular processes, which were previously not known to be related. For example, we found two clusters with high density (high intra-cluster protein associations) to be enriched for ribosomal proteins, translation and ribosome biogenesis, as well as oxidative phosphorylation, lysosomes, and interferon signaling (clusters 6 and 7). Other enriched and correlated processes include proteasome together with spliceosome (cluster 2) and glycolysis together with tRNA aminoacylation and focal adhesion (cluster 8). To exclude dominance of the differences between healthy tissue and the tumors, we constructed an additional network comprising of correlations between tumor samples only, with a correlation cutoff of 0.5 ( Figure S2A ). In this analysis, we found highest correlations within specific functions, mostly consisting of large protein complexes such as ribosomes (cluster 1), spliceosome (cluster 5), oxidative phosphorylation (cluster 7), and DNA replication (cluster 6). Beyond these, we further found high correlations between distinct compartments, such as mitochondrial oxidative phosphorylation and the peroxisome (cluster 7), and distinct functions, such as translation and lysosomal degradation (cluster 5) or DNA replication and locomotion (cluster 6). These results highlight the potential of this proteomic resource to reveal fundamental cancer-related associations of cellular processes, which can serve as the basis for further functional research.
Comparison of Healthy and Tumor Tissue Proteomes
Next, we examined the unsupervised distribution of the samples in our cohort. Principal component analysis revealed that the first component separates between the healthy tissues and the tumor samples, including the lymph node metastases ( Figure 3A ). All tumor samples (primary LNN and LNP) and metastases were indistinguishable according to the first two components. In agreement, correlation matrix of primary tumors and healthy tissue showed major differences between the healthy tissue and tumors, as well as co-clustering of primary tumors and lymph node metastases, highlighting their similar protein expression patterns ( Figure 3B ). The correlations between samples ranged from 0.06 to 0.87. The median correlation between healthy and primary tumors was 0.38 (and 0.39 for matched samples), and the median correlation between primary tumors and lymph node metastases was 0.58 (and 0.75 for matched samples). To our surprise, we found that the correlation within the tumor sample group (both primary and lymph node metastases) was significantly higher than the correlation among the healthy tissues ( Figure S2B , p < 0.0001). Examination of the variance of protein expression within each group of samples showed enrichment of extracellular matrix part in the proteins with highest SD (2D annotation enrichment; FDR = 0.02) ( Figure S2C ) . These ECM proteins originate from imperfect dissection of the tissues, which is more prominent in the healthy ducts due to their small size ( Figure S2D , left). While the ECM proteins contributed to the inter-tumor variance ( Figure S2D , right), they constitute only 3%-5% of the tissue mass, and upon data normalization, these do not affect the overall ratio distribution (see Experimental Procedures). Supervised investigation of the differences between the healthy tissues and tumors identified 969 significantly different proteins, with 563 significantly upregulated proteins in the tumors and 406 proteins downregulated in tumors (Welch's t test; FDR = 0.05; Table S4A ). More than 95% of these proteins are well within the 5-fold ratio toward the standard and are therefore considered to be accurately determined (Figures S3A and S3B) . Initial investigation of the significantly changing proteins showed that two known breast cancer markers, Mucin 1 (CA15-3) (Kufe, 2013) and cathepsin D (Wolf et al., 2003) , are more highly expressed in the breast cancer tissues compared to normal duct epithelia ( Figure S3C ). Next, we performed enrichment analysis of gene ontology (GO) and KEGG pathways aimed at the identification of key processes that are up-or downregulated in the cancer tissues versus the healthy samples (Table  S5A ). This analysis showed significant changes in two major groups of cellular processes: (1) protein homeostasis and quality control, and (2) central metabolism.
Protein Homeostasis Alteration in Tumors
Cellular protein levels are controlled by a plethora of housekeeping functions that regulate their synthesis, mainly transcription and translation, and post-translational control of protein folding and stability. As the basis of these, genomic instability increases the extent of aberrant proteins. In agreement, DNA repair proteins were found to be significantly downregulated in tumors (p = 1e-8) ( Figure S3D ). These include components of non-homologous end joining (NHEJ) complex Ku (XRCC5 and XRCC6), both components of MutS alpha mismatch repair system (MSH2 and MSH6), as well as condensin complex (SMC2 and SMC4) and PARP1, which have a role in single-strand DNA break repair (Wu and Yu, 2012) . In addition, we found a significant decrease in UPF1 (Table S4A ) and also lower levels of UPF2, two proteins that act in the nonsense-mediated mRNA decay (NMD) pathway. Potentially, reduced activity of the NMD can lead to translation of truncated proteins with deleterious gain of function or dominant negative activity (Chang et al., 2007) .
At the level of regulation of protein synthesis and degradation, we found a highly significant enrichment and upregulation of See also Figure S2A and Table S3 . , and H/M (right) ratios at 0 hr, 2 hr, 4 hr, 9 hr, 12 hr, and 24 hr after the pulse. Graphs represent mean of two biological replicates. ***p < 0.002. ribosomal proteins, both cytosolic and mitochondrial (p = 9e-75; Figure 3C ), suggesting an elevated rate of protein translation. While the demand for protein production is expected, we found that fundamental translation auxiliary proteins, namely the aminoacyl tRNA synthetases (ARSs), were surprisingly downregulated in the tumors (p = 2.6e-13; Figure S3D ). The ARSs have a canonical role in translation regulation, however, recent evidence also point to non-canonical roles, which may also affect tumorigenesis (see Discussion). An additional level of regulation involves proper protein folding. In normal cells, accumulation of unfolded proteins would result in the activation of ER chaperones that collectively act under the unfolded protein response (UPR) (Ma and Hendershot, 2004) . Interestingly, major players in this response-namely, GRP78 (HSPA5), GRP94 (HSP90B1), and GRP170 (HYOU1), as well as six out of eight core subunits of the TRiC/CCT chaperonin complex and the chaperone calnexin-were significantly downregulated in tumors relative to normal tissue ( Figure S3D ; Table S4A ). The substantial deregulation of protein folding machinery may lead to increased amounts of unfolded proteins, a state tightly linked with stress and disease (Ma and Hendershot, 2004) .
We reasoned that the increased mal-production of proteins may increase the need to degrade them. Indeed, we found that seven protein components of the 20S core proteolytic structure of the proteasome were significantly upregulated (PSMA1, PSMA5, PSMB1, PSMB2, PSMB3, PSMB4, and PSMB8) (Figure 3C ) suggesting an increase in proteasomal activity. Interestingly, five members of the 19S regulatory complex (PSMC1, PSMC2, PSMD1, PSMD2, and PSMD7) were significantly downregulated, which may implicate alteration of substrate recognition and binding (Liu and Jacobson, 2013) . Lysosomal proteins were also significantly upregulated (p = 1.1e-12) ( Figure S3D ) with the most prominent components belonging to the vacuolar-type proton ATPase (ATP6V0D1, ATP6AP1) and four cathepsins (CTSA, CTSB, CTSD, CTSZ). Taken together, our results suggest that protein homeostasis is impaired in tumor cells, and tumors may over-produce improperly functioning proteins, which may interfere with proper cellular activities and thus facilitate tumorigenesis.
In order to validate the higher protein turnover in tumor cells, we conducted a pulsed-SILAC experiment in normal mammary epithelial cells (HMEC) versus ER-positive breast cancer cells (MCF7). To that end, cells were fully labeled with medium-heavy lysine and arginine (Lys4 and Arg6) followed by pulse-labeling with heavy amino acids (Lys8 and Arg10) and then mixed with light-labeled cells as a common standard. Proteomic analysis of the samples showed that in agreement with the tumor data, the H/L ratios (representing protein synthesis), M/L ratios (representing degradation), and H/M ratios (representing turnover), were all significantly higher in MCF7 cells than in HMEC (Figure 3D) , supporting the functional output of the increased levels of ribosomal proteins, proteasome, and lysosomes in the tumors.
Metabolic Remodeling in Tumor Samples
Two central metabolic pathways were found to be enriched in the significantly changing proteins: oxidative phosphorylation proteins were significantly upregulated in the cancer samples; concurrently, key glycolytic enzymes such as HK2, GAPDH, ALDOA, LDHA, and LDHB were downregulated ( Figures 3C  and S3D ). We further validated the increased activity of the electron transport chain in tumor cells by activity-based assays for mitochondrial complex I and complex IV, using breast cancer tumor arrays (Figures S3E and S3F) .
We zoomed in on the entire metabolic network, to elucidate the individual regulated pathways. We matched our data to the Recon 1 human metabolic network, which includes 3,300 metabolic reactions assigned to over 2,000 proteins (Duarte et al., 2007) and averaged the expression values of all proteins that are assigned to a specific Recon 1 pathway in every sample. A comparison between the healthy ducts and the tumors identified overall 18 upregulated and 16 downregulated pathways between healthy and tumor tissues ( Figures 4A, 4B , and S4; Table S5B). Oxidative phosphorylation was highly upregulated (p = 8e-13) alongside with increases in ROS detoxification enzymes (p = 0.01), while glycolysis was downregulated (p = 0.004) (Figure 4B) . Two metabolic pathways branching from glycolytic intermediates, namely the pentose phosphate pathway (PPP) and the serine/glycine biosynthetic pathway, were also downregulated (p = 0.005 and 2e-7, respectively), primarily due to the significant reduction in expression of branching enzymes glucose-6-phosphate dehydrogenase (G6PD) and phosphoglycerate dehydrogenase (PHGDH) ( Figure 4B) . Interestingly, our results suggest reduced biosynthesis and increased breakdown of fatty acids. ATP-citrate lyase (ACLY), a key enzyme that produces acetyl-CoA for lipid and cholesterol biosynthesis, was significantly downregulated in tumors (p = 8e-7; Figure 4B ). Fatty acid synthase (FASN), the primary enzyme in lipid synthesis, was also lower in expression. We observed a very prominent decrease in the biosynthesis of cholesterol (p = 1e-7), with five enzymes significantly downregulated ( Figure 4B ). Concurrently, several enzymes in the peroxisomal b-oxidation pathway were significantly elevated, pointing to potential utilization of this pathway to generate reducing power in the form of NADH. Two components of the malate/aspartate shuttle, which transports the NADH from the cytosol to the mitochondria, were also significantly upregulated ( Figure 4B ).
We found that tumor cells exhibit significantly elevated levels of glutamine synthase (GLUL), which uses ammonia and glutamate to produce glutamine. Concurrently, the reverse reaction, catalyzed by glutaminase (GLS) was significantly reduced, suggesting higher glutamine production ( Figures 4A and 4B) . In support of this, the major importer for glutamine, SLC1A5, was significantly downregulated, as well as the bidirectional transporter SLC7A5/SLC3A2, which has been shown to control outward efflux of glutamine in exchange for essential amino acids (Nicklin et al., 2009 ). Finally, we found that the reactiveoxygen species (ROS) detoxification pathway was significantly upregulated (p = 0.01), with increased expression of peroxiredoxin (PRDX)-3, PRDX-4, and PRDX-5, glutathione peroxidase (GPX)-1 and GPX-4, and superoxide dismutase (SOD)-1 ( Figure 4B) .
As a validation of the proteomic results, we selected three metabolic enzymes that were higher in the cancer samples compared to the healthy tissue and represent key regulated pathways: (1) GLUL, a key regulator of Gln production; (2) SLC25A11, a member of the malate-aspartate shuttle; and (3) acyl-CoA thioesterase (ACOT1), which operates in the b-oxidation of fatty acids (Hunt et al., 2012) . IHC on tumor microarrays showed that, in agreement with our proteomic results, ACOT1 and GLUL were absent in the healthy tissue and dramatically increased in the tumor samples ( Figures 4C and S5A) . SLC25A11 was lowly expressed in healthy epithelia but was highly increased in tumor samples. In addition, we selected 12 proteins from the downregulated set and 24 proteins from the upregulated set and examined their expression in the Human Protein Atlas database (http:// www.proteinatlas.org/) based on IHC on tissue microarrays (Uhlé n et al., 2015). Nine ER-positive, Her2-negative cases were examined against up to three cases of healthy breast ducts. Representative figures are shown in Figure S5B . Ten of the downregulated proteins and 12 of the upregulated proteins showed a pattern of staining that matches the proteomic findings ( Figure S5C ; Table S6 ). Presumably, some of the discrepancies result from the semiquantitative nature of IHC and potential (B) Expression changes of metabolic enzymes between healthy tissue and primary tumors, grouped by Recon 1 metabolic pathways. yp < 0.02; *p < 0.01; **p < 0.001; ***p < 0.0001; unmarked, not significant. (C) The overexpression of three metabolic enzymes-glutamine synthetase (GLUL), acyl-CoA thioesterase (ACOT1), and oxoglutarate/malate carrier (SLC25A11) was validated using IHC on tumor arrays. See also Figures S4 and S5A. non-specific binding of some of the antibodies. Importantly, only one of the antibodies (against POSTN) showed strong extracellular staining and no staining of epithelial cells, and six additional antibodies showed mild involvement of extracellular staining. These results indicate that macrodissection of the tissues allowed capturing of the cancer-related proteome, with minor effects of the extracellular proteins.
Finally, we compared the protein expression data of five enriched categories to mRNA expression data published by the Cancer Genome Atlas Network (2012). We analyzed the expression values of 22 healthy controls and 358 luminal tumors ( Figure 5 ). Interestingly, we found that the mRNA expression of ribosomal proteins is reduced in tumors while protein levels are significantly elevated, in agreement with known post-transcriptional regulation on ribosome synthesis (Henras et al., 2008) . An opposite trend is seen in glycolytic proteins and DNA repair proteins. Oxidative phosphorylation and lysosome gene expression was elevated on both transcript and protein levels, however, protein increases were significantly larger than mRNA. Taken together, these data demonstrate only partial protein-RNA concordance in both protein production and metabolic pathways.
Changes in Protein Expression during Cancer Progression
Next, we aimed to identify proteins and processes that discriminate between LNN and LNP tumors and between LNP tumors and their matched metastases. To verify that the proteomic changes between these sample groups genuinely represent aggressiveness and not the existence of different luminal subtypes (luminal A and B), we examined the levels of ki67, a marker of luminal B tumors, and found similar levels of ki67 in LNN compared to LNP ( Figure S6A ). We identified 78 upregulated and 8 downregulated proteins in LNP tumors compared to LNN (Welch's t test, FDR = 0.05; Table S4B ). Network analysis showed that the processes associated with the elevated cancer stage mirror those of tumor formation (compared to the healthy tissues; Figure 6A ). Similarly, 27 of the upregulated proteins were structural ribosomal proteins; seven mitochondrial proteins were upregulated. Splicing machinery was also enriched, including the spliceosome itself (p = 1e-9; Fisher exact test, FDR = 0.02) and additional splicing proteins-particularly in the context of ribosomal RNA processing. Interestingly, the expression of 15 proteins was significantly altered both between healthy tissue and primary LNN tumor and between LNN and LNP primary lesions ( Figure S6B ). Twelve of them -mostly ribosomal proteins-were upregulated twice; the cytoskeletallinking protein plectin (PLEC) was downregulated twice, and methionyl aminopeptidase (METAP)-2 and purine nucleoside phosphorylase (PNP) were downregulated in LNN tumors but upregulated in LNP tumors.
We next examined the metastatic tissue from lymph nodes in comparison to the primary tumors. In an unsupervised clustering, 12 cases of matched tissues (from the same Table S4C ). Bars represent medians + SEM. See also Figure S6 . patient) clustered together, with a significantly higher correlation compared to all other unmatched tumor-metastasis couples (average 0.75 versus 0.58) ( Figures 6B and 6C ). The 563 proteins that were significantly upregulated in tumor tissue compared to healthy tissue, and the 406 downregulated proteins showed a similar median expression in lymph node metastases compared to the primary tumors ( Figure 6D ). In contrast to hundreds of proteins differentially expressed between healthy and tumor tissues, only four proteins were significantly upregulated and six were downregulated in the LN (Table S4C ). Four of the downregulated proteins-POSTN, COL12A1, CDKN2A, and LGALS1-displayed a bidirectional trend (increased in the primary tumor and decreased in LN; Figure 6E ). Given the extracellular staining of POSTN and COL12A1 (based on the Human Protein Atlas database), reduced expression probably stems from the change in the microenvironment of the lymph nodes compared to the breast. Together, these data demonstrate that the proteomic profile of lymph node metastases is highly similar to that of the primary tumors as the primary site of cancer dissemination.
DISCUSSION
Our work presents genome-scale proteomic analysis of breast cancer progression, which is able to capture aspects of cancer development not evident from large-scale genomic and transcriptomic studies. In a three-level comparison, we capture the functional difference between healthy tissue and tumors, between primary tumors and lymph node metastases, and between lymph node-negative and -positive breast cancer.
Beyond the analysis performed within the current study, these data can serve the cancer community as a basis for understanding fundamental processes involved in tumor development and allow the uncovering of novel protein-protein associations.
Breakdown of Translational Quality Control Processes
The most prominent network of upregulated proteins in tumors consisted of ribosomal proteins, with a concurrent downregulation of several of the most important co-players of the translational machinery-the tRNA aminoacyl synthetases (ARSs) and the auxiliary protein AIMP2. The canonical role of the ARSs is to ligate an amino acid to its cognate tRNA, later to be added to the nascent polypeptide chain. Improper activity of the ARSs may impair the accuracy of protein synthesis and hamper appropriate folding of proteins . Furthermore, even when proteins are correctly translated, the marked decrease in the expression of important chaperons may also have an adverse effect on their function. This, in turn, can inflict tumorigenesis if the misfolded proteins are tumor suppressors, as has been demonstrated for p53 (Xu et al., 2011) and VHL (McClellan et al., 2005) . Alternatively, it can induce gain-of-function activities or interfere with protein localization (Valastyan and Lindquist, 2014) . In recent years, increasing evidence point to additional, non-canonical roles that may make the ARSs important regulators of diverse cellular functions, including activation of P53, interaction with transcription factors, and regulation of angiogenesis . AIMP2 mediates anti-proliferative and pro-apoptotic functions through regulation of ubiquitination, and as an outcome, mice lacking this protein died neonatally due to severe over-proliferation of lung epithelia (Kim et al., 2003 , making AIMP2 a bona fide tumor suppressor. Further functional analyses will elucidate the roles of tRNA aminoacyl synthetases in tumorigenesis in the case of luminal breast tumors. We propose that the elevated rate of protein production and degradation, together with downregulation of several quality control systems (DNA damage response, NMD, chaperones), impairs protein homeostasis in the cancer cells. Damaged proteins may eventually be degraded by the proteasome or by lysosomal proteases, overall increasing protein turnover rates. Higher lysosomal and proteasomal activity has been previously reported in breast cancer (Deng et al., 2007; Kern et al., 2015) . In a broader context, and despite the tremendous energetic demand of such a mechanism, we speculate that it provides the system the necessary adaptability to changing conditions and confers an evolutionary advantage to the cancer cells. We suggest that this energetic demand is met by elevated respiration and ATP production.
Metabolic Alterations in ER-Positive Tumors
The link between neoplastic transformation and cell metabolism has gained much attention in recent years as an emerging hallmark of cancer (Hanahan and Weinberg, 2011) ; however, it is becoming evident that the metabolic adaptations differ dramatically between cancer types. We have identified five major metabolic features in ER-positive primary breast tumors, namely (1) reduced glycolysis, (2) increased cellular respiration, (3) increased breakdown and reduced synthesis of fatty acids, (4) reduced glycolytic branching to pentose phosphate pathway and serine synthesis, and (5) decreased uptake and increased production of glutamine. These metabolic results are in marked contrast to the known Warburg effect. The downregulation of glycolysis is particularly intriguing as it implies the need for an alternative source of reducing power to serve the high demand of cellular respiration. We suggest that this force comes from peroxisomal b-oxidation, and the NADH formed by this pathway is shunted to the mitochondria via an upregulated malate/aspartate shuttle system to supply the electron transport chain. In parallel to elevated levels of fatty acid utilization, the initiating enzymes of de novo fatty acids synthesis-namely ATP citrate lyase (ACLY) and, to a lesser extent, fatty acid synthase (FASN)-are downregulated, together with significant reduction of cholesterol synthesis. In agreement, a recent IHC study reported negative staining of FASN in 66% of 376 luminal tumors (Kim et al., 2015) . We propose that the proximity of the cancer cells to adipose tissue within the breast may enable higher uptake and utilization of fatty acids to supply its energetic demands. By that, the invading cancer cells are selected for their ability to adapt to their unique microenvironment. Some major differences concerning amino acid metabolism were found between ER-positive and ER-negative breast cancer cells. For example, basal-like tumors, which are mostly ERnegative, predominantly rely on glutamine uptake, while ER-positive luminal cells produce more glutamine through the activity of glutamine synthetase (GLUL) (Jerby et al., 2012; Kung et al., 2011) . In agreement, we found elevated levels of this enzyme in tumors compared to healthy tissues and lower levels of the major glutamine importer SLC1A5. In another example, Possemato et al. (2011) show that serine synthesis is an essential component in the metabolism of ER-negative cell lines. In agreement, phosphoglycerate dehydrogenase (PHGDH), the enzyme that acts on the glycolytic intermediate 3-phosphoglycerate to initiate serine synthesis, was found to be highly expressed in ER-negative breast cancer, and flux through serine to a-ketoglutarate was found to serve as an anaplerotic source for the TCA cycle (Possemato et al., 2011) . Our results show lower levels of PHGDH in ER-positive breast cancer. This implies that the ultimate function of serine as an anaplerotic source is revoked in light of citrate availability in the mitochondria and reducing power that stems from fatty acid catabolism.
We therefore propose the notion that ER-positive tumors adapt to their surrounding by utilizing fatty acids for energy production and growth, and this mechanism minimizes the reliance on extracellular glucose and glutamine by shifting the anabolic core to glutamine synthesis. The differences between ER-positive and ER-negative cells show that tumor metabolism must be analyzed in context and they emphasize the fact that breast cancer subtypes differ not only in genomic landscape and clinical outcome, but also in their metabolic characteristics.
Proteomic Profiles of Lymph Node Metastases Are Similar to Those of Primary Tumors
The comparison between primary tumors and their matched lymph node metastases showed high similarity in protein expression. This is in agreement with several gene expression studies that examined both lymph node metastases and distant metastases (reviewed in Suzuki and Tarin, 2007) . Four proteins-POSTN, LGALS1, CDKN2A, and COL12A1-were upregulated in primary tumors and downregulated in metastases. Both POSTN (periostin) and LGALS1 (galectin-1) have been shown to promote invasiveness in ovarian carcinoma and lung cancer, respectively, by interacting with integrins (Gillan et al., 2002; Hsu et al., 2013) , and collagens of types VIII and XI were reported to be associated with high expression levels in tumors in comparison to metastases (Suzuki and Tarin, 2007) .
In conclusion, we present a deep proteomic analysis of breast cancer progression and provide a high-quality proteomic database of the results. These data provide functional insights regarding breast cancer development, which are largely distinct from mRNA-based studies, thus reinforcing the importance of the proteomic approach. The concentration on a single breast cancer subtype provided a unique view of breast cancer, highlighting the complexity and phenotypic variability of this disease.
EXPERIMENTAL PROCEDURES
The complete experimental procedures are described in the Supplemental Information.
Cohort Assembly FFPE blocks were obtained from the Department of Pathology (Sheba Medical Center, Israel) on approval of the local IRB committee. Included cases were ER-positive and Her2-negative infiltrating ductal carcinoma of the breast. Tumors with no lymph node metastases were classified as LNN primary tumors (n = 21). Tumors with at least one lymph node involved by macro-metastatic carcinoma were classified as LNP primary tumors (n = 20). Lymph node metastatic tissues (n = 25, 20 cases matched to LNP primary tumors) were obtained from lymph nodes dissected during breast surgery. Healthy breast duct epithelia tissues (n = 11 from LNN patients, n = 11 from LNP patients) were obtained from the surgical borders of the specimen, defined by pathologists as ''tumor free.'' For the full cohort refer to Table S1 .
Sample Preparation FFPE blocks were sliced into twelve 10-mm thick sections, and high cellularity regions were isolated to enrich for cancer cells (or healthy breast epithelia). Proteins were denatured, combined at a 1:1 ratio with the previously described super-SILAC mix (Geiger et al., 2010) and digested following the FFPE-FASP protocol . Peptides were fractionated by strong anion exchange (SAX) fractionation in a StageTip format (Wi sniewski et al., 2009 ).
MS Analysis
Peptides were separated by nano-ultra high performance liquid chromatography (UHPLC) (Easy-nLC1000, Thermo Fisher Scientific) coupled on-line to a Q-Exactive or Q-Exactive Plus mass spectrometers (Thermo Fisher Scientific) through the EASY-Spray ionization source. Peptides were eluted with 4 hr linear gradient of water:acetonitrile. Tandem mass spectrometry (MS/MS) spectra were acquired in a data-dependent manner with the top ten precursor m/z values from each MS scan fragmented by higher-energy collisional dissociation (HCD).
Data Analysis
MS raw files were analyzed by MaxQuant (version 1.5.0.36) (Cox and Mann, 2008) . MS/MS spectra were searched against the human Uniprot database (published November 2014) by the Andromeda search engine . False discovery rate (FDR) of 0.01 was used on both the peptide and protein levels and determined by a decoy database. Prior to bioinformatics analysis, the resulting protein list was filtered to eliminate common contaminants and decoy database hits. For complete list of identified proteins see Table S2 . All raw MS-files, MS-analysis result files, and experimental design are available in the ProteomeXchange consortium: PXD000815.
Bioinformatic and Statistical Analysis
Bioinformatic and statistical analyses were performed in the Perseus software (http://www.perseus-framework.org/) and in MATLAB (version R2014a). For all analyses, we filtered the data to include only proteins quantified in >70% of the samples. Ratios toward internal standard were normalized by Z scoring and subtracting most frequent value on each sample, and missing data points were imputed by creating a normal distribution with a width of 0.3 and a downshift of 1.5. Welch's t tests for statistical significance were performed with permutation-based FDR correction threshold of 0.05. Fisher exact tests for annotation enrichments were performed with FDR threshold of 0.02 against the human proteome. 1D and 2D annotation enrichment were performed as described .
Pulsed-SILAC Assay
Human mammary epithelial cells (HMEC) and the ER-positive breast cancer cell line MCF7 were fully labeled with medium-heavy lysine and arginine (Lys4 and Arg6) (Cambridge Isotopes Laboratories). Culture medium containing heavy versions of the same amino acids (Lys8 and Arg10) was pulsed into the medium-labeled cell lines at T = 0, and harvested at 0 hr, 2 hr, 4 hr, 9 hr, 12 hr, and 24 hr. At each time point, cell lysates were mixed with the same cells grown in light culture medium that serve as an internal standard. Lysates were digested overnight with trypsin in solution and were subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis and MaxQuant analysis as described above.
Immunohistochemistry
Breast cancer FFPE tumor microarrays were obtained from BioChain Institute and stained with anti-ACOT1 and anti-SLC25A11 (AbCam) or anti-GLUL (Sigma-Aldrich/Prestige antibodies). Staining intensity of relevant cores (ERpositive, Her2-negative invasive ductal carcinomas, and healthy ducts) was assessed by a pathologist on a scale of 0 (no staining) to 3 (strong staining). 
